Age (years) | 6–75 (median 39.3) |
Sex (Male/Female) | 13/8 |
Clinical presentation | |
Thyroid mass | 17/18 (94.4%) |
Rapid growing | 12/18 (66.7%) |
Dyspnea | 11/18 (61.1%) |
Dysphagia | 3/18 (16.7%) |
Thyrotoxicosis | 1/18 (5.6%) |
Cavernous sinus syndrome | 1/18 (5.6%) |
*B symptoms | 4/14 (28.6%) |
Associated immuosuppressive condition | 0/21 (0%) |
Tumor size (mm) (median size) | 20–105 (59) |
Other organ involvement at diagnosis | 11/21 (52.4%) |
Lymph nodes involvement | 11/21 (52.4%) |
Above diaphragm | 7/11 (63.6%) |
Above and below diaphragm | 4/11 (36.4%) |
Clinical stage at presentation | |
I | 6/21 (28.6%) |
II | 2/21 (9.5%) |
III | 2/21 (9.5%) |
IV | 11/21 (52.4%) |
Elevated thyroid function | 2/8 (25%) |
Elevated TSH | 1/2 (50%) |
Elevated thyroglobulin | 1/2 (50%) |
Elevated thyroid antibody | 4/8 (50%) |
Hashimoto’s thyroiditis | 5/7 (71.4%) |
Immunohistochemistry | |
CD3 | 0/7(0%) |
CD5 | 0/8(0%) |
CD10 | 14/14 (100%); |
CD20 (n = 18) | 18/18 (100%) |
CD21 (n = 2) | 0 (0%) |
CD30 (n = 2) | 0 (0%) |
CD43 (n = 3) | 1/3 (33.3%) |
CD79a (n = 5) | 5/5 (100%) |
TDT (n = 3) | 0 (0%) |
IgG (n = 1) | 0 (0%) |
IgA (n = 1) | 0 (0%) |
IgM (n = 1) | 1/1 (100%) |
Kappa (n = 2) | 1/2 (50%) |
Lambda (n = 1) | 1/1 (100%) |
Bcl-2 (n = 10) | 0 (0%) |
Bcl −6 (n = 6) | 5/6 (83.3%) |
MUM-1 (n = 2) | 1/2 (50%) |
p16 (n = 1) | 1/1 (100%) |
p53 (n = 1) | 0/1 (0%) |
Ki-67 labelling index (> 90%) | 19/19 (100%) |
MDM2 (n = 1) | 1/1 (100%) |
EBER ISH | 0/12 (0%) |
Translocation t(8;14) (n = 12) | 12/12 (100%) |
CD10 + (Flow cytometry) | 5/5 (100%) |
Treatment | |
Chemotherapy only | 12/20 (60%) |
Surgery + Chemotherapy | 7/20 (35%) |
Surgery + Chemotherapy + Radiotherapy | 1/20 (5%) |
Follow-up (months) (median) | 0.5–361(46.5 m) |
Clinical outcome | |
Alive with complete remission | 14/19 (73.7%) |
Alive with persistent disease | 1/19 (5.3%) |
Dead of disease | 4/19 (21.1%) |